WO1999021574A3 - Enhancement of morphogen activity - Google Patents

Enhancement of morphogen activity Download PDF

Info

Publication number
WO1999021574A3
WO1999021574A3 PCT/US1998/022655 US9822655W WO9921574A3 WO 1999021574 A3 WO1999021574 A3 WO 1999021574A3 US 9822655 W US9822655 W US 9822655W WO 9921574 A3 WO9921574 A3 WO 9921574A3
Authority
WO
WIPO (PCT)
Prior art keywords
morphogen
enhancement
activity
enhancing
morphogen activity
Prior art date
Application number
PCT/US1998/022655
Other languages
French (fr)
Other versions
WO1999021574A2 (en
WO1999021574A9 (en
Inventor
Marc F Charette
David C Rueger
Dennis Higgins
Original Assignee
Creative Biomolecules Inc
Marc F Charette
David C Rueger
Dennis Higgins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc, Marc F Charette, David C Rueger, Dennis Higgins filed Critical Creative Biomolecules Inc
Priority to CA002307826A priority Critical patent/CA2307826A1/en
Priority to JP2000517732A priority patent/JP2002506000A/en
Priority to AU11220/99A priority patent/AU1122099A/en
Priority to EP98953989A priority patent/EP1027059A2/en
Publication of WO1999021574A2 publication Critical patent/WO1999021574A2/en
Publication of WO1999021574A3 publication Critical patent/WO1999021574A3/en
Publication of WO1999021574A9 publication Critical patent/WO1999021574A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides methods and compositions for enhancing morphogen activity in mammals, including humans. The methods involve the administration of a molecule capable of releasing morphogen inhibition. The molecule can be administered either alone or in combination with a morphogen. The present invention further provides screening methods for indentifying a molecule capable of enhancing morphogen activity.
PCT/US1998/022655 1997-10-27 1998-10-26 Enhancement of morphogen activity WO1999021574A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002307826A CA2307826A1 (en) 1997-10-27 1998-10-26 Enhancement of morphogen activity
JP2000517732A JP2002506000A (en) 1997-10-27 1998-10-26 Enhanced morphogen activity
AU11220/99A AU1122099A (en) 1997-10-27 1998-10-26 Enhancement of morphogen activity
EP98953989A EP1027059A2 (en) 1997-10-27 1998-10-26 Enhancement of morphogen activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6362497P 1997-10-27 1997-10-27
US60/063,624 1997-10-27

Publications (3)

Publication Number Publication Date
WO1999021574A2 WO1999021574A2 (en) 1999-05-06
WO1999021574A3 true WO1999021574A3 (en) 1999-07-08
WO1999021574A9 WO1999021574A9 (en) 1999-08-12

Family

ID=22050440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/022655 WO1999021574A2 (en) 1997-10-27 1998-10-26 Enhancement of morphogen activity

Country Status (5)

Country Link
EP (1) EP1027059A2 (en)
JP (1) JP2002506000A (en)
AU (1) AU1122099A (en)
CA (1) CA2307826A1 (en)
WO (1) WO1999021574A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2104678C (en) 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
WO2001075135A1 (en) * 2000-03-30 2001-10-11 Oxford Biomedica (Uk) Limited Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6696410B1 (en) 1999-09-27 2004-02-24 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
CA2385887A1 (en) * 1999-09-27 2001-04-05 John C. Lee Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
JP2005500027A (en) * 2001-06-11 2005-01-06 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Methods for increasing survival of dopamine secreting cells
JP4555924B2 (en) * 2003-02-24 2010-10-06 中外製薬株式会社 Spinal cord injury therapeutic agent containing interleukin-6 antagonist
CA2554644C (en) 2004-02-02 2015-06-16 Pioneer Hi-Bred International, Inc. Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use
US20110167516A1 (en) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Methods and compositions for the introduction and regulated expression of genes in plants
WO2011082310A2 (en) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040771A1 (en) * 1995-06-07 1996-12-19 Creative Biomolecules, Inc. SINGLE CHAIN ANALOGS OF THE TGF-β SUPERFAMILY (MORPHONS)
WO1997005285A2 (en) * 1995-07-26 1997-02-13 Creative Biomolecules, Inc. Methods and compositions for identifying morphogen analogs
WO1997007135A2 (en) * 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040771A1 (en) * 1995-06-07 1996-12-19 Creative Biomolecules, Inc. SINGLE CHAIN ANALOGS OF THE TGF-β SUPERFAMILY (MORPHONS)
WO1997005285A2 (en) * 1995-07-26 1997-02-13 Creative Biomolecules, Inc. Methods and compositions for identifying morphogen analogs
WO1997007135A2 (en) * 1995-08-14 1997-02-27 Creative Biomolecules, Inc. Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof

Also Published As

Publication number Publication date
WO1999021574A2 (en) 1999-05-06
EP1027059A2 (en) 2000-08-16
CA2307826A1 (en) 1999-05-06
JP2002506000A (en) 2002-02-26
AU1122099A (en) 1999-05-17
WO1999021574A9 (en) 1999-08-12

Similar Documents

Publication Publication Date Title
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
AU4217499A (en) Composition having therapeutic and/or nutritionally active substituent
AU3136897A (en) Compositions, methods and devices for the transdermal delivery of drugs
HUP0004408A3 (en) Actuator for an inhalater for delivering medicament and an inhalater with such an actuator
FI973828A (en) Compounds and compositions for administering the active ingredients
HUP9601566A3 (en) Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component
EP1178786A4 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CA2255891A1 (en) Compositions and methods for treating or preventing diseases of body passageways
WO2000007979A3 (en) Compounds and compositions for delivering active agents
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
CA2254079A1 (en) Androstene derivatives
HK1019205A1 (en) Galenic preparation for prevention and treatment of hepatocarcinoma.
WO1999021574A3 (en) Enhancement of morphogen activity
ATE229338T1 (en) 2',2'-DIFLUORNUCLEOSIDES FOR IMMUNOSUPPRESSIVE THERAPY AND COMBINATION PREPARATIONS
CA2401191A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
EE200000226A (en) 3,6-Half-Ketals of the 9a-Azalides, Method of Preparation and Pharmaceutical Composition
EP0683668A4 (en) Compositions and methods for transdermal drug delivery.
AU2418499A (en) Org-5222 in the treatment of depression
EE04263B1 (en) A pharmaceutical composition for increasing the bioavailability of piperidinoalkanol anthihamine and its derivatives and for treating allergic reactions in a patient.
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
AU2662799A (en) Modified pharmacologically active agents and improved therapeutic methods employing same
WO1999047150A3 (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
AU1027501A (en) Substance capable of controlling the inclusion of exon 10 of the tau gene, and its therapeutic use against tauopathies
IL135520A0 (en) 8-azabicyclo [3.2.1.] octane-3-methanamine derivatives, their preparation and their therapeutic application
AU7836798A (en) Compositions for delivery of biological agents and methods for the preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

WWE Wipo information: entry into national phase

Ref document number: 11220/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998953989

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2307826

Country of ref document: CA

Ref country code: CA

Ref document number: 2307826

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 517732

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1998953989

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09509648

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 1998953989

Country of ref document: EP